Recent Updates
Recently added Catalysts
CLDX

Celldex Therapeutics Announces Upcoming Presentation at Leerink Swann Global Healthcare Conference 2013

Key Takeaway: NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Leerink Swann Global Healthcare Conference 2013 on Wednesday

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Leerink Swann Global Healthcare Conference 2013 on Wednesday, February 13, 2013 at 11:30 am ET at The Waldorf Astoria New York.
A live webcast of the presentation will be available online on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.
Last updated: Feb 11, 2013